Cocrystal Pharma Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

COCP$1.11+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

	September 30, 2024	December 31, 2023
(unaudited)
Assets
Current assets:
Cash	$13,020	$26,353
Restricted cash	75	75
Tax credit receivable	652	890
Prepaid expenses and other current assets	509	1,773
Total current assets	14,256	29,091
Property and equipment, net	181	271
Deposits	29	46
Operating lease right-of-use assets, net (including $163 and $42 respectively, to related party)	1,767	1,851
Total assets	$16,233	$31,259
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$1,655	$3,022
Current maturities of operating lease liabilities (including $55 and $42 respectively, to related party)	293	240
Total current liabilities	1,948	3,262
Long-term liabilities:
Operating lease liabilities (including $163 and $0 respectively, to related party)	1,582	1,613
Total liabilities	3,530	4,875
Commitments and contingencies (Note 8)	-	-
Stockholders’ equity:
Common stock, $0.001 par value 100,000 and 150,000 shares authorized as of September 30, 2024, and December 31, 2023; 10,174 shares issued and outstanding as of September 30, 2024 and December 31, 2023	10	10
Additional paid-in capital	342,845	342,288
Accumulated deficit	(330,152)	(315,914)
Total stockholders’ equity	12,703	26,384
Total liabilities and stockholders’ equity	$16,233	$31,259

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.